Pfizer's $11.6 bn Biohaven buy could spark more biotech deals

The deal, announced on Tuesday, is the biggest in the sector so far this year and ends a dearth of large acquisitions, which along with clinical failures and investor exits following a gradual easing of the pandemic have pummeled biotech stocks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UfQcaJ3
via IFTTT